Cell therapy in solid tumours
CAR-T, TIL and TCR-T therapies for solid tumours.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 56, 62, 51, 51, 39.
New guidelines and consensus this year
- IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19 Infections in Immunocompromised PatientsClin Infect Dis2026 Aug 24
- Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendationsBone Marrow Transplant2025 Nov
All papers from the last 12 months
853 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Preclinical evaluation of homodimeric FAPI target modules for UniCAR-mediated targeting of FAP-expressing tumor and stromal cellsOncoimmunology2026 Dec 31PMID 42627862
- The LXRβ/NF-κB axis reprograms CAR-T cells to resist exhaustion in the tumor microenvironmentOncoimmunology2026 Dec 31PMID 41496523
- Preclinical evaluation of SLC35D3-targeted CAR-T cells for tumor-selective immunotherapyBiochem Biophys Rep2026 DecPMID 42830742
- Knowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics studyHum Vaccin Immunother2026 DecPMID 42316771
- Fine-tuning affinity and spacer design enhances T cell potency in DLL3 and BCMA CAR T cellsMAbs2026 DecPMID 41383027
- Multifaceted roles of chemokines in gastric cancer: From tumor microenvironment modulation to therapeutic targeting (Review)Oncol Lett2026 NovPMID 42798813Review
- The role of chimeric antigen receptor (CAR) T cell therapy in breast cancerInt Immunopharmacol2026 Nov 1PMID 42612349Review
- Emerging Landscape of CAR-T Cell Therapy in Colon Cancer: Mechanistic Insights, Clinical Advances, Challenges, and Future DirectionsPathol Res Pract2026 NovPMID 42574910Review
- The landscape of genetic medicines for in vivo T cell reprogrammingAdv Drug Deliv Rev2026 NovPMID 42546776Review
- Resistance to CAR-based cell therapy: Mechanisms and overcoming strategiesDrug Resist Updat2026 NovPMID 42497563Review
More oncology trends
All specialties →Bispecific antibodies in solid tumours
Bispecific antibodies such as tarlatamab, amivantamab and ivonescimab.
Personalised cancer vaccines
mRNA and neoantigen vaccines tailored to a patient's tumour.
AI in cancer pathology
Deep learning on digital pathology slides.
CDK4/6 inhibitors in breast cancer
Palbociclib, ribociclib and abemaciclib in hormone receptor-positive breast cancer.
Radioligand therapy
Radioactive drugs that target tumour receptors, such as lutetium-177 PSMA.
Key point: Most international guidelines endorse 177Lu-PSMA-617 for PSMA-positive metastatic castration-resistant prostate cancer after prior ARPI and taxane chemotherapy.
KRAS inhibitors
Drugs targeting KRAS mutations, such as sotorasib and adagrasib.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("CAR-T"[tiab] OR "CAR T"[tiab] OR "TIL therapy"[tiab] OR lifileucel[tiab] OR "TCR-T"[tiab]) AND ("solid tumor*"[tiab] OR "solid tumour*"[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.